We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · December 21, 2020

Palbociclib + Endocrine Therapy in Heavily Pretreated HR+/HER2− Advanced Breast Cancer

The Breast

 

Additional Info

The Breast
Palbociclib Combined With Endocrine Therapy in Heavily Pretreated HR+/HER2− Advanced Breast Cancer Patients: Results From the Compassionate Use Program in Spain (PALBOCOMP)
Breast 2020 Nov 13;[EPub Ahead of Print], L Manso, C Hernando, M Galán, M Oliveira, MA Cabrera, R Bratos, CA Rodríguez, M Ruiz-Borrego, S Blanch, A Llombart-Cussac, JI Delgado-Mingorance, I Álvarez-Busto, I Gallegos, L González-Cortijo, S Morales, E Aguirre, BA Hernando, A Ballesteros, JE Alés-Martínez, C Reboredo, A Oltra, M González-Cao, M Santisteban, D Malón, I Echeverría, E García-Garre, E Vega, S Servitja, R Andrés, CE Robles, R López, E Galve, MJ Echarri, M Legeren, F Moreno

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading